Currently, good manufacturing practice (GMP)-compliant production of Lv-PD1-γδ T cells has been established, and we are preparing for an investigator-initiated trial (IIT) in patients with ovarian cancer in the clinic. Here, PDCD1 is linked to ovarian cancer.